Vancomycin: Difference between revisions

From IDWiki
()
(: added spectrum of activity)
Line 3: Line 3:
*A [[:Category:Glycopeptides|glycopeptide]] antibiotic
*A [[:Category:Glycopeptides|glycopeptide]] antibiotic


===Mechanism of action===
===Mechanism of Action===


*Inhibits cross-linking of peptidoglycans in the cell wall
*Inhibits cross-linking of peptidoglycans in the cell wall

=== Mechanisms of Resistance ===

* Alterations in peptidoglycans conferred by chromosomal or plasmid-mediated ''vanA'', ''vanB'', or ''vanC''

=== Spectrum of Activity ===

* Broadly active against Gram-positive bacteria, including anaerobes
* Not active against Gram-negative bacteria
* Notable resistance occurs in:
** [[Clostridium innocuum]]
** [[Enterococcus gallinarum]], [[Enterococcus casseliflavus]], and [[Enterococcus flavus]] (chromosomal ''vanC'')
** [[Erysipelothrix rhusiopathiae]]
** [[Lactobacillus]], except [[Lactobacillus acidophilus]] and [[Lacobacillus delbrueckii]]
** [[Leuconostoc]]
** [[Pediococcus]]
** [[Weissella]]


===Pharmacodynamics===
===Pharmacodynamics===

Revision as of 16:13, 21 August 2020

Background

Mechanism of Action

  • Inhibits cross-linking of peptidoglycans in the cell wall

Mechanisms of Resistance

  • Alterations in peptidoglycans conferred by chromosomal or plasmid-mediated vanA, vanB, or vanC

Spectrum of Activity

Pharmacodynamics

  • Efficacy predicted by AUC to MIC ratio

Indications

  • Suspected or confirmed MRSA

Dosing

  • Common dose
    • Loading dose of 25-30 mg/kg given once for serious infections
    • 15 mg/kg/dose with timing based on renal function (q12h if normal)
    • Titrate based on monitoring parameters (below)
    • Adjustments assume linear pharmacokinetics,so a doubling of the daily dose, for example, should double the trough or AUC:MIC

Obesity

  • Dosing should use actual body weight, with a maximum loading dose of 3 g

Monitoring

  • Based on PK/PD modelling, the trough level was previously used to dose vancomycin
    • Serum trough drawn within hour before fourth dose
    • 10-15 for low-risk infections
    • 15-20 for high-risk Staphylococcus aureus infections such as osteomyelitis, meningitis, and bacteremia
  • Current guidelines recommend AUC:MIC monitoring using Bayesian calculators1
    • Use peak 60 min after infusion and trough 1 to 60 minutes before next dose, and record times accurately
    • Target AUC/MICBMD ratio of 400 to 600 for serious Staphylococcus aureus infections

Adverse Reactions

Renal Failures

  • Risk factors
    • Prolonged courses >21 days
    • Higher trough
    • Concomitant nephrotoxic medication
    • Older age
    • CKD/AKI
    • Liver disease
    • Peritonitis
    • Neutropenia
    • Male sex
  • Mechanism of injury: oxidative stress in the proximal tubular cells

Red Person Syndrome

  • Rash, pruritis, and hypotension, with onset of vancomycin, resolves on stopping
  • Very high incidence previously
  • Histamine-mediated
  • Can decrease dose or prolong infusion, prophylactic antihistamines

References

  1. ^  Michael J Rybak, Jennifer Le, Thomas P Lodise, Donald P Levine, John S Bradley, Catherine Liu, Bruce A Mueller, Manjunath P Pai, Annie Wong-Beringer, John C Rotschafer, Keith A Rodvold, Holly D Maples, Benjamin M Lomaestro. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy. 2020. doi:10.1093/ajhp/zxaa036.